



October 19, 2005

## **Encision Launches New enTouch™ Handle**

Boulder, Colorado, October 19, 2005 -- Encision Inc. (Amex: ECI), a medical device company with patented surgical technology emerging as a standard of care in minimally-invasive surgery, announced the launch of its new enTouch handle for its articulating instruments.

“We are pleased to launch this new handle which is designed to address customer satisfaction and retention,” said Jack Serino, President and CEO of Encision. “Encision handles represent approximately 9% of the company’s revenue while the articulating instrument inserts they operate represent approximately 62%.”

“enTouch handles offer improved ergonomics and less hand fatigue for surgeons. The enTouch family of laparoscopic instrumentation combines active electrode monitoring for patient safety with smooth and predictable control in a light-weight design for surgeon satisfaction.”

Encision Inc. designs and manufactures innovative surgical devices that allow the surgeon to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase revenues through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.

CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600, [mmchaffie@encision.com](mailto:mmchaffie@encision.com)